Peripheral CD34+ Stem Cells Beneficial in Angina

Share this content:
Peripheral CD34+ Stem Cells Beneficial in Angina
Peripheral CD34+ Stem Cells Beneficial in Angina

WEDNESDAY, July 20, 2016 (HealthDay News) -- Mobilization of peripheral CD34+ stem cells may be beneficial for patients with angina pectoris, according to a study presented at the American Heart Association's Basic Cardiovascular Sciences 2016 Scientific Sessions, held from July 18 to 21 in Phoenix.

Hadyanto Lim, Ph.D., from the Methodist University of Indonesia in North Sumatra, and colleagues examined whether intravenous transplantation of mobilized autologous peripheral blood CD34+ stem cells provides beneficial effects for patients with angina pectoris. Fifteen patients (four women and 11 men) with intractable angina pectoris were administered granulocyte colony stimulating factor (G-CSF) once a day for mobilization of CD34+ cells into the peripheral blood. On day four of the G-CSF, leukapheresis procedure was initiated.

The researchers found that after leukapheresis, intravenous peripheral blood CD34+ cells and total white blood cell count increased (both P < 0.001). Treatment had no effect on indices of high-sensitivity C-reactive protein, platelets, hemoglobin, alanine aminotransferase, lactic dehydrogenase, and uric acid. Angina frequency was significantly lower after intravenous CD34+ cells at week four (P < 0.001). Improvement in exercise tolerance was significantly higher after stem cell transplantation (P < 0.001). Mild myalgia was reported by most patients, which was managed easily with acetaminophen.

"Using G-CSF to isolate CD34-harboring stem cells, called CD34+ stem cells, for transplantation back into the patient may be a practical alternative for hard-to-treat patients," Lim said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »